Charles Schwab’s Immix Biopharma IMMX Stock Holding History

Charles Schwab’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Buy	127,256 +99,794	+363%	+$926K	﹤0.01%	2919
2026 Q1	$250K	Buy	+27,462	New	+$202K	﹤0.01%	3280

Other funds holding IMMX

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Charles Schwab's IMMX Position: Q2 2026 in Review

Charles Schwab increased its Immix Biopharma (IMMX) stake by 363% in Q2 2026, buying an estimated $926K and bringing the position to 127,256 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2919.

Charles Schwab first reported a position in IMMX in Q1 2026 and has held it in 2 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

Charles Schwab held 127,256 shares of Immix Biopharma worth $1.31M as of Q2 2026.
Charles Schwab bought 99,794 Immix Biopharma shares in Q2 2026, an estimated $926K.
Immix Biopharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2919 holding.
Charles Schwab first reported a position in Immix Biopharma in Q1 2026 and has held it in 2 quarters since.
109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.